DSM to Sell Participation in DEXPlastomers JV to Borealis
For DSM, a sale of DEXPlastomers is in line with its long-term focus of being a Life Sciences and Materials Sciences company, active in health, nutrition and materials.
13 Nov 2012 --- Royal DSM, the global Life Sciences and Materials Sciences company, announced that it has reached an agreement with Borealis AG for the sale of DEXPlastomers V.o.F, a 50/50 Joint Venture of DSM with an affiliate of ExxonMobil Chemical. DSM will also sell its LldPE Compact Solution Technology to Borealis. Subject to customary approvals and notifications, the transaction is expected to close in Q1 2013.
Established in 1996, DEXPlastomers is a 50/50 joint venture between DSM and Exxon Chemical Holland Ventures B.V., producing C8 plastomers and linear low density polyethylene. DSM’s LldPE Compact Solution Technology was developed in the 1960’s to produce polyethylenes in a certain density range and is instrumental to the operations of DEXPlastomers.
In 2012, DEXPlastomers anticipates sales of approximately €180 million. Currently, 95 DSM employees are in the scope of the transaction.
For DSM, a sale of DEXPlastomers is in line with its long-term focus of being a Life Sciences and Materials Sciences company, active in health, nutrition and materials. DSM’s 50% participation in DEXPlastomers is reported under Corporate Activities in DSM’s accounts.
